Comments sought on issuing multiple prescriptions
The Drug Enforcement Administration has requested comments on a proposed rule to amend its regulations concerning issuance of multiple prescriptions for schedule II controlled substances, which are drugs or other substances that have a high potential for abuse.
The DEA has proposed to allow practitioners to provide individual patients with multiple prescriptions, to be filled sequentially, for the same schedule II controlled substance, allowing a patient to receive over time up to a 90-day supply of that controlled substance.
The DEA's proposed rule follows the publication of a clarification in the Federal Register in August 2005, "Clarification Of Existing Requirements Under The Controlled Substances Act For Prescribing Schedule II Controlled Substances" (see JAVMA, Nov. 15, 2005).
Written comments on the DEA's proposed amendment to its regulations concerning issuance of multiple prescriptions for schedule II controlled substances must be postmarked, and electronic comments must be sent, on or before Nov. 6.
If submitting by mail, label the comment "Docket No. DEA-287N" and mail it to Deputy Administrator, Drug Enforcement Administration, Washington, DC 20537, Attention: DEA Federal Register Representative/ODL. Send express mail to DEA Headquarters, Attention: DEA Federal Register Representative/ODL, 2401 Jefferson-Davis Highway, Alexandria, VA 22301. Comments may also be e-mailed to dea [dot] diversion [dot] policy
usdoj [dot] gov (dea[dot]diversion[dot]policy[at]usdoj[dot]gov) or submitted through the Federal eRulemaking portal at www.regulations.gov.
For further information, contact Mark W. Caverly, Chief, Liaison and Policy Section, Office of Diversion Control, Drug Enforcement Administration, Washington, DC 20537; phone (202) 307-7297.